These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21188453)

  • 1. A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study).
    Sagawa A; Fujisaku A; Ohnishi K; Mukai M; Yasuda I; Amasaki Y; Shimizu M; Ichikawa K; Ohsaki H
    Mod Rheumatol; 2011 Jun; 21(3):251-7. PubMed ID: 21188453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
    Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
    Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA.
    Iwatani M; Inoue E; Nakamura T; Nakajima A; Hara M; Tomatsu T; Kamatani N; Yamanaka H
    Mod Rheumatol; 2006; 16(6):376-80. PubMed ID: 17165000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis.
    Sekiguchi N; Kameda H; Amano K; Takeuchi T
    Mod Rheumatol; 2006; 16(2):85-91. PubMed ID: 16633927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis.
    Nakajima M; Ueda N; Ohara H; Abe M; Kinoshita M
    Mod Rheumatol; 2009; 19(4):384-9. PubMed ID: 19363607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis.
    Nagashima M; Matsuoka T; Saitoh K; Koyama T; Kikuchi O; Yoshino S
    Clin Exp Rheumatol; 2006; 24(3):260-7. PubMed ID: 16870092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis. epidemiology of DMARDs treatment in Japan.
    Nagashima M; Shu G; Yamamoto K; Yamahatsu S; Yoshino S
    Clin Exp Rheumatol; 2005; 23(1):27-35. PubMed ID: 15789884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study.
    Suda A; Nagaoka S; Ohono S; Ideguchi H; Soga T; Ishigatsubo Y
    Mod Rheumatol; 2008; 18(6):609-14. PubMed ID: 18682889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential influences of bucillamine and methotrexate on the generation of fibroblast-like cells from bone marrow CD34+ cells of rheumatoid arthritis patients.
    Hirohata S; Yanagida T; Tomita T; Yoshikawa H
    Int Immunopharmacol; 2009 Jan; 9(1):86-90. PubMed ID: 19000788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
    Proudman SM; James MJ; Spargo LD; Metcalf RG; Sullivan TR; Rischmueller M; Flabouris K; Wechalekar MD; Lee AT; Cleland LG
    Ann Rheum Dis; 2015 Jan; 74(1):89-95. PubMed ID: 24081439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
    Koyama Y; Shiraishi H; Ohta T; Uchino A
    Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity.
    Tymms K; Zochling J; Scott J; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Roberts L; Arnold M; Littlejohn G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):190-6. PubMed ID: 23983001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis.
    Ogasawara M; Tamura N; Kageyama M; Onuma S; Kusaoi M; Toyama S; Sekiya F; Matsudaira R; Nawata M; Tada K; Matsushita M; Kempe K; Amano H; Morimoto S; Yamaji K; Takasaki Y
    Clin Rheumatol; 2012 Feb; 31(2):251-7. PubMed ID: 21773713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis.
    Matsuno H; Okada M; Sakai Y; Abe C; Katayama K; Sagawa A; Yamasaki K; Kondo M; Funahashi K; Matsubara T
    Mod Rheumatol; 2016; 26(1):51-6. PubMed ID: 26052803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.